These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 30271152)

  • 61. Long-acting Injectable vs. Oral Antipsychotics: Adherence, Persistence and Switching over three Years of Real-life Analysis.
    Romagnoli A; Santoleri F; Costantini A
    Curr Rev Clin Exp Pharmacol; 2021; 16(1):109-116. PubMed ID: 32148198
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Trend survey on adverse event profiles of antipsychotic long-acting injections and oral agents using the Japanese adverse drug event report database.
    Hatano M; Kamei H; Shimato A; Yamada S; Iwata N
    Psychiatry Res; 2020 Sep; 291():113249. PubMed ID: 32603929
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics.
    Toja-Camba FJ; Gesto-Antelo N; Maroñas O; Echarri Arrieta E; Zarra-Ferro I; González-Barcia M; Bandín-Vilar E; Mangas Sanjuan V; Facal F; Arrojo Romero M; Carracedo A; Mondelo-García C; Fernández-Ferreiro A
    Pharmaceutics; 2021 Jun; 13(7):. PubMed ID: 34201784
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Long-Acting Injectable Second-Generation/Atypical Antipsychotics for the Management of Bipolar Disorder: A Systematic Review.
    Keramatian K; Chakrabarty T; Yatham LN
    CNS Drugs; 2019 May; 33(5):431-456. PubMed ID: 30963507
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents.
    Jann MW; Penzak SR
    CNS Drugs; 2018 Mar; 32(3):241-257. PubMed ID: 29569082
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Real-life persistence of long-acting injectable antipsychotics in schizophrenic patients: A retrospective observational study in France
.
    Guillon P; Harmand S; Ansolabehere X
    Int J Clin Pharmacol Ther; 2019 Sep; 57(9):437-444. PubMed ID: 31232279
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.
    Maher AR; Theodore G
    J Manag Care Pharm; 2012 Jun; 18(5 Suppl B):S1-20. PubMed ID: 22784311
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
    Kim E; Correll CU; Mao L; Starr HL; Alphs L
    CNS Spectr; 2016 Dec; 21(6):466-477. PubMed ID: 27629292
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ethnic and Age Disparities in Patients Taking Long-acting Injectable Atypical Antipsychotics.
    Soleman M; Lam N; Woo BK
    Cureus; 2017 Oct; 9(10):e1772. PubMed ID: 29238631
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies.
    Kishimoto T; Hagi K; Kurokawa S; Kane JM; Correll CU
    Lancet Psychiatry; 2021 May; 8(5):387-404. PubMed ID: 33862018
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A Systemic Review and Experts' Consensus for Long-acting Injectable Antipsychotics in Bipolar Disorder.
    Chou YH; Chu PC; Wu SW; Lee JC; Lee YH; Sun IW; Chang CL; Huang CL; Liu IC; Tsai CF; Yen YC
    Clin Psychopharmacol Neurosci; 2015 Aug; 13(2):121-8. PubMed ID: 26243837
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Hyperprolactinemia in psychotic patients treated in monotherapy with long-acting injectable antipsychotics.
    Bonete Llácer JM; Martínez Hortelano A; Richart Albelda B
    Int J Psychiatry Clin Pract; 2019 Sep; 23(3):189-193. PubMed ID: 30848967
    [No Abstract]   [Full Text] [Related]  

  • 73. [Long acting injectable antipsychotics in the treatment of schizophrenia: a review of literature].
    Graffino M; Montemagni C; Mingrone C; Rocca P
    Riv Psichiatr; 2014; 49(3):115-23. PubMed ID: 25000887
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Evaluation of long-acting injectable antipsychotics with the corresponding oral formulation in a cohort of patients with schizophrenia: a real-world study in Spain.
    García-Carmona JA; Simal-Aguado J; Campos-Navarro MP; Valdivia-Muñoz F; Galindo-Tovar A
    Int Clin Psychopharmacol; 2021 Jan; 36(1):18-24. PubMed ID: 33086252
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study.
    Cai Q; Patel C; Kim E; Connolly N; Tunceli O; El Khoury AC
    Adv Ther; 2019 Apr; 36(4):858-869. PubMed ID: 30848442
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort.
    Guinart D; Taipale H; Rubio JM; Tanskanen A; Correll CU; Tiihonen J; Kane JM
    Schizophr Bull; 2021 Oct; 47(6):1621-1630. PubMed ID: 34013325
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?
    Maestri TJ; Mican LM; Rozea H; Barner JC
    Psychopharmacol Bull; 2018 Mar; 48(3):8-15. PubMed ID: 29713100
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Risk of withdrawal of consent for treatment with long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled trials.
    Yaegashi H; Misawa F; Noda H; Fujii Y; Takeuchi H
    Schizophr Res; 2021 Mar; 229():94-101. PubMed ID: 33309187
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials.
    Majer IM; Gaughran F; Sapin C; Beillat M; Treur M
    J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123183
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.